WealthShield Partners’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

WealthShield Partners’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$215K	Hold	70,154	–	–	0.02%	332
2025 Q4	$250K	Hold	70,154	–	–	0.03%	307
2025 Q3	$245K	Hold	70,154	–	–	0.03%	302
2025 Q2	$144K	Hold	70,154	–	–	0.02%	349
2025 Q1	$80K	Buy	+70,154	New	+$54.3K	0.01%	391
2024 Q2	–	Sell	-24,126	Closed	-$38.1K	–	489
2024 Q1	$38.1K	Hold	24,126	–	–	0.01%	356
2023 Q4	$49.2K	Buy	+24,126	New	+$41.8K	0.01%	361

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WealthShield Partners's STLN Position: Q1 2026 in Review

WealthShield Partners held its Starling Oncology Institute, Inc. Common Stock (STLN) position steady in Q1 2026 at 70,154 shares worth $215K. The position accounts for 0.02% of the portfolio, ranked #332.

WealthShield Partners first reported a position in STLN in Q4 2023 and has held it in 7 quarters since. The position peaked at $250K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

WealthShield Partners held 70,154 shares of Starling Oncology Institute, Inc. Common Stock worth $215K as of Q1 2026.
WealthShield Partners left its Starling Oncology Institute, Inc. Common Stock share count unchanged in Q1 2026.
Starling Oncology Institute, Inc. Common Stock made up 0.02% of WealthShield Partners's portfolio in Q1 2026, its #332 holding.
WealthShield Partners first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2023 and has held it in 7 quarters since.
WealthShield Partners's Starling Oncology Institute, Inc. Common Stock position peaked at $250K in Q4 2025.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on WealthShield Partners's 13F filing for Q1 2026, filed 1 May 2026.